Virta Health has reported improved outcomes from its Phase II randomised controlled trial, which examined the impact of its medically supervised nutrition therapy on patients with stage IV metastatic pancreatic cancer. The study, conducted with partners such as Mayo Clinic, HonorHealth Research Institute, and USC Norris Comprehensive Cancer Center, found that the therapy extended survival in comparison to chemotherapy. The group receiving nutrition therapy lived 34% longer than those in the control group, averaging 13.7 months versus 10.2 months. The results suggest that nutritional intervention could offer benefits beyond traditional drug development.